In reply: Why remifentanil?

J Anesth. 2018 Jun;32(3):459. doi: 10.1007/s00540-018-2487-7. Epub 2018 Apr 3.

Authors

Wataru Sakai¹, Yusuke Yoshikawa², Michiaki Yamakage²

Affiliations

¹ Department of Anesthesiology, Sapporo Medical University School of Medicine, West 16, South 1, Chuouku, Sapporo, Hokkaido, 060-8556, Japan. sakaiwataru1128@gmail.com.
² Department of Anesthesiology, Sapporo Medical University School of Medicine, West 16, South 1, Chuouku, Sapporo, Hokkaido, 060-8556, Japan.

PMID: 29616346
DOI: 10.1007/s00540-018-2487-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Acute Kidney Injury*
Anesthetics, Intravenous
Cardiopulmonary Bypass
Humans
Incidence
Remifentanil*

Substances

Anesthetics, Intravenous
Remifentanil